CollPlant Biotechnologies Ltd Ordinary Shares (CLGN) is a publicly traded Healthcare sector company. As of May 21, 2026, CLGN trades at $0.45 with a market cap of $6.27M and a P/E ratio of 0.00. CLGN moved +0.00% today. Year to date, CLGN is -68.75%; over the trailing twelve months it is -77.27%. Its 52-week range spans $0.27 to $5.00. Rallies surfaces CLGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CollPlant Ends AbbVie Partnership, Halves Staff to Extend Cash Runway to Q4 2026: CollPlant terminated its five-year dermal and soft tissue filler agreement with AbbVie and is seeking new aesthetic partnerships. The company is cutting about 50% of its workforce to extend cash runway into Q4 2026 and advance regenerative aesthetics, breast implants and 3D bioprinting bioinks.
| Metric | Value |
|---|---|
| Price | $0.45 |
| Market Cap | $6.27M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.00 |
| 52-Week Low | $0.27 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
CLGN analyst coverage data. Average price target: $0.00.